Co-led by new investors aMoon and Luma Group, Bausch + Lomb, Jefferson Life Sciences and others also participated in the funding, which will accelerate the advancement of pipeline precision therapies ...

Retinitis pigmentosa (RP) is a rare inherited condition that causes the gradual death of photoreceptors (light-sensing cells) ...

Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of ...

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

Researchers have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to ...

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

To apply a precision medicine approach to this disease, Character Bio has partnered with over 150 ophthalmology treatment ...

With promising results in animal models, researchers are now planning clinical trials to evaluate the safety and ...

National Institutes of Health researchers develop eye drops that slow vision loss in animals: Maryland Monday, March 24, 2025, 16:00 Hrs [IST] Researchers at the National Institut ...

Metagenomi (NASDAQ:MGX – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies ...